Sign inJoin waitlistJoin the waitlist

Sumithira Vasu

Physician · Ohio State University College of Medicine

Credentials: · · · ·

History

Ohio State University College of Medicine
Present

Hematology
2004–2005
Internal Medicine
2001–2004
Doctor of Medicine
1997–2001

Research

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
New England Journal of Medicine · 2019 · 354 citations
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic…
Journal of Clinical Oncology · 2022 · 165 citations
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Journal of Clinical Oncology · 2021 · 134 citations

SD
Steven Devine
34 papers
SP
Sam Penza
31 papers
Samantha Jaglowski
31 papers
Alice Mims
24 papers
KL
Karilyn Larkin
24 papers · 1 as a fellow
William Blum
24 papers
Don Benson
22 papers
JB
John Byrd
20 papers
Sarah Wall
20 papers · 2 as a fellow
Hannah Choe
19 papers · 1 as a fellow
YE
Yvonne Efebera
19 papers
Rebecca Klisovic
18 papers

Grants

BMT Core- The Ohio State University Blood and Marrow Transplant Research Consortium
National Heart, Lung, and Blood Institute · UG1
Contact PI · $2M · Ohio State University
2011–2031
Trispecific CAR-T Cells Targeting CD19, CD20 and CD22 to Treat B-Cell Malignancies
National Cancer Institute · R01
Contact PI · $2.4M · Ohio State University
2023–2028
MIDAS: MIcroangiopathy, Endothelial Damage in Adults Undergoing Stem Cell Transplantation
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.8M · Ohio State University
2020–2026

Clinical trials

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Principal investigator · Active not recruiting · Phase 1
Ohio State University Comprehensive Cancer Center
2026
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Principal investigator · Recruiting · Phase 1
Sumithira Vasu
2022–2027
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
Principal investigator · Recruiting · Early phase 1
Sumithira Vasu
2020–2026
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Principal investigator · Completed · Phase 1
Sumithira Vasu
2020–2024